Research programme: small molecule therapeutics - Boehringer Ingelheim/Evotec AG

Drug Profile

Research programme: small molecule therapeutics - Boehringer Ingelheim/Evotec AG

Alternative Names: CB2 receptor agonists - Boehringer Ingelheim/Evotec; Enzyme modulators - Boehringer Ingelheim/Evotec; GPCR modulators - Boehringer Ingelheim/Evotec; Ion channel modulators - Boehringer Ingelheim/Evotec

Latest Information Update: 26 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim; Evotec AG
  • Developer Boehringer Ingelheim; Evotec AG; Evotec NeuroSciences
  • Class Benzylamines; Small molecules; Sulfonamides
  • Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Immunological disorders; Inflammation; Pain; Respiratory tract disorders
  • Research CNS disorders
  • Phase Unknown Metabolic disorders

Most Recent Events

  • 19 Jun 2014 Preclinical development is ongoing
  • 26 Sep 2012 Preclinical trials in Cancer in Germany (unspecified route)
  • 26 Sep 2012 Preclinical development is ongoing Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top